製品番号: HY-15298

Grazoprevir

(別名: MK-5172)

29 Cited Publications

カスタマーレビュー

Based on 29 publication(s) in Google Scholar

Grazoprevir (MK-5172) is a selective inhibitor of Hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants, with K_is of 0.01 nM (gt1b), 0.01 nM (gt1a), 0.08 nM (gt2a), 0.15 nM (gt2b), 0.90 nM (gt3a), respectively. Grazoprevir inhibits SARS-CoV-2 3CL^pro activity.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 99.90%
CAS 番号: 1350514-68-9
分子式: C₃₈H₅₀N₆O₉S
分子量:766.90

保管条件:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months

Grazoprevir 構造式

CAS 番号: 1350514-68-9

容量

価格（税別）

在庫状況

数量

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

お問い合わせ Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability お問い合わせ Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

バルクお問い合わせ

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- IC₅₀ & Target
- Cellular Effect
- 体外実験
- 体内実験
化学情報
Publications (29)
溶剤 & 溶解度
- 体外
- 体内
プロトコル
純度とドキュメンテーション
参考文献
Help & FAQs
Bioz

生物活性

製品説明

Grazoprevir (MK-5172) is a selective inhibitor of Hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants, with K_is of 0.01 nM (gt1b), 0.01 nM (gt1a), 0.08 nM (gt2a), 0.15 nM (gt2b), 0.90 nM (gt3a), respectively^[1]^[2]. Grazoprevir inhibits SARS-CoV-2 3CL^pro activity^[3].

IC₅₀ & Target

Ki: 0.01±<0.01 nM (gt1b), 0.01±0.01 nM (gt1a), 0.08±0.02 nM (gt2a), 0.15±0.06 nM (gt2b), 0.90±0.2 nM (gt3a)^[1]

Cellular Effect

Cell Line	Type	Value	Description	References
Huh-7	EC₅₀	0.2 nM Compound: GZR; MK-5172	Antiviral activity against HCV genotype 1b infected in human Huh7 cells incubated for 96 hrs by luciferase assay Antiviral activity against HCV genotype 1b infected in human Huh7 cells incubated for 96 hrs by luciferase assay	[PMID: 34405680]
Huh-7	EC₅₀	0.3 nM Compound: MK-5172	Antiviral activity against HCV genotype 1a infected in human HuH7 cells assessed as inhibition of viral replication after 72 hrs by RT-PCR method Antiviral activity against HCV genotype 1a infected in human HuH7 cells assessed as inhibition of viral replication after 72 hrs by RT-PCR method	[PMID: 26819676]
Huh-7	EC₅₀	0.3 nM Compound: MK-5172	Antiviral activity against HCV genotype 1b infected in human HuH7 cells assessed as inhibition of viral replication after 72 hrs by RT-PCR method Antiviral activity against HCV genotype 1b infected in human HuH7 cells assessed as inhibition of viral replication after 72 hrs by RT-PCR method	[PMID: 26819676]
Huh-7	EC₅₀	0.6 nM Compound: 1; MK-5172	Antiviral activity against HCV genotype 1a infected in human HuH7 cells assessed as reduction viral RNA level after 72 hrs by RT-PCR method Antiviral activity against HCV genotype 1a infected in human HuH7 cells assessed as reduction viral RNA level after 72 hrs by RT-PCR method	[PMID: 27994759]
Huh-7	EC₅₀	0.6 nM Compound: 1; MK-5172	Antiviral activity against HCV genotype 1b infected in human HuH7 cells assessed as reduction viral RNA level after 72 hrs by RT-PCR method Antiviral activity against HCV genotype 1b infected in human HuH7 cells assessed as reduction viral RNA level after 72 hrs by RT-PCR method	[PMID: 27994759]
Huh-7	EC₅₀	1.2 nM Compound: MK-5172	Antiviral activity against HCV genotype 2a infected in human HuH7 cells assessed as inhibition of viral replication after 72 hrs by RT-PCR method Antiviral activity against HCV genotype 2a infected in human HuH7 cells assessed as inhibition of viral replication after 72 hrs by RT-PCR method	[PMID: 26819676]
Huh-7	EC₅₀	1.5 nM Compound: MK-5172	Antiviral activity against Hepatitis C virus genotype 1b infected in HuH7 cells assessed as reduction in replicon RNA level after 72 hrs by TaqMan-based RT-PCR analysis in presence of 10% FBS Antiviral activity against Hepatitis C virus genotype 1b infected in HuH7 cells assessed as reduction in replicon RNA level after 72 hrs by TaqMan-based RT-PCR analysis in presence of 10% FBS	[PMID: 24900818]
Huh-7	EC₅₀	12 nM Compound: GZR; MK-5172	Antiviral activity against HCV genotype 1b harboring D168A mutant infected in human Huh7 cells incubated for 96 hrs by luciferase assay Antiviral activity against HCV genotype 1b harboring D168A mutant infected in human Huh7 cells incubated for 96 hrs by luciferase assay	[PMID: 34405680]
Huh-7	EC₅₀	13 nM Compound: MK-5172	Antiviral activity against Hepatitis C virus genotype 3a infected in HuH7 cells assessed as reduction in replicon RNA level after 72 hrs by TaqMan-based RT-PCR analysis in presence of 10% FBS Antiviral activity against Hepatitis C virus genotype 3a infected in HuH7 cells assessed as reduction in replicon RNA level after 72 hrs by TaqMan-based RT-PCR analysis in presence of 10% FBS	[PMID: 24900818]
Huh-7	EC₅₀	261 nM Compound: GZR; MK-5172	Antiviral activity against HCV genotype 1b harboring A156T mutant infected in human Huh7 cells incubated for 96 hrs by luciferase assay Antiviral activity against HCV genotype 1b harboring A156T mutant infected in human Huh7 cells incubated for 96 hrs by luciferase assay	[PMID: 34405680]
Huh-7	EC₅₀	5 nM Compound: MK-5172	Antiviral activity against HCV genotype 2b infected in human HuH7 cells assessed as inhibition of viral replication after 72 hrs by RT-PCR method Antiviral activity against HCV genotype 2b infected in human HuH7 cells assessed as inhibition of viral replication after 72 hrs by RT-PCR method	[PMID: 26819676]
Huh-7	EC₅₀	5.4 nM Compound: 1; MK-5172	Antiviral activity against HCV genotype 2a infected in human HuH7 cells assessed as reduction viral RNA level after 72 hrs by RT-PCR method Antiviral activity against HCV genotype 2a infected in human HuH7 cells assessed as reduction viral RNA level after 72 hrs by RT-PCR method	[PMID: 27994759]
Huh-7	EC₅₀	7.2 nM Compound: 1; MK-5172	Antiviral activity against HCV genotype 3a infected in human HuH7 cells assessed as reduction viral RNA level after 72 hrs by RT-PCR method Antiviral activity against HCV genotype 3a infected in human HuH7 cells assessed as reduction viral RNA level after 72 hrs by RT-PCR method	[PMID: 27994759]
Huh-7	EC₅₀	7.2 nM Compound: MK-5172	Antiviral activity against HCV genotype 3a infected in human HuH7 cells assessed as inhibition of viral replication after 72 hrs by RT-PCR method Antiviral activity against HCV genotype 3a infected in human HuH7 cells assessed as inhibition of viral replication after 72 hrs by RT-PCR method	[PMID: 26819676]
Huh-7	IC₅₀	7 nM Compound: 15, MK-5172	Antiviral activity against Hepatitis C virus genotype 1a infected in human HuH7 cells assessed as inhibition of viral replication after 24 hrs presence of 40% NHS Antiviral activity against Hepatitis C virus genotype 1a infected in human HuH7 cells assessed as inhibition of viral replication after 24 hrs presence of 40% NHS	[PMID: 24900473]
Huh-7	IC₅₀	7.4 nM Compound: 15, MK-5172	Antiviral activity against Hepatitis C virus (isolate Con1) genotype 1b infected in human HuH7 cells assessed as inhibition of viral replication after 24 hrs in presence of 50% NHS Antiviral activity against Hepatitis C virus (isolate Con1) genotype 1b infected in human HuH7 cells assessed as inhibition of viral replication after 24 hrs in presence of 50% NHS	[PMID: 24900473]

体外実験

In biochemical assays, Grazoprevir (MK-5172) is effective against a panel of major genotypes and variants engineered with common resistant mutations, with K_i of 0.01±<0.01 nM (gt1b), 0.01±0.01 nM (gt1a), 0.08±0.02 nM (gt2a), 0.15±0.06 nM (gt2b), 0.90±0.2 nM (gt3a), 0.07±0.01 nM (gt1b^R155K), 0.14±0.03 nM (gt1b^D168V), 0.30±0.04 nM (gt1b^D168Y), 5.3±0.9 nM (gt1b^A156T), and 12±2 nM (gt1b^A156V), respectively. In the replicon assay, Grazoprevir demonstrates subnanomolar to low-nanomolar EC₅₀s against genotypes 1a, 1b, and 2a, with EC₅₀s of 0.5±0.1 nM, 2±1 nM, and 2±1 nM for gt1b^con1, gt1a, and gt2a, respectively. Grazoprevir is potent against a panel of HCV replication mutants NS5A (Y93H) (EC₅₀=0.7±0.3 nM), NS5B nucleosides (S282T) (EC₅₀=0.3±0.1 nM), and NS5B (C316Y) (EC₅₀=0.4±0.2)^[1]. Grazoprevir (MK-5172) maintains the excellent potency against the gt 3a enzyme as well as a broad panel of mutant enzymes, has excellent potency in the replicon system [gt1b IC₅₀(50% NHS)=7.4 nM; gt1a IC₅₀(40% NHS)=7 nM], and shows excellent rat liver exposure^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

体内実験

Grazoprevir (MK-5172) demonstrates efficacy in vivo against chronic-HCV-infected chimpanzees^[1]. When dosed to dogs, Grazoprevir (MK-5172) shows low clearance of 5 mL/min/kg and a 3 h half-life after iv dosing and has good plasma exposure (AUC=0.4 μM h) after a 1 mg/kg oral dose. Dog liver biopsy studies showed that the liver concentration of Grazoprevir after the 1 mg/kg oral dose is 1.4 μM at the 24 h time point. Similar to its behavior in rats, Grazoprevir demonstrates effective partitioning into liver tissue and maintains high liver concentration, relative to potency, 24 h after oral dosing in dogs^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

化学情報

CAS 番号 1350514-68-9
性状 Solid
分子量 766.90
分子式 C₃₈H₅₀N₆O₉S
Color White to off-white
SMILES

COC1=CC2=C(N=C(CCCCC[C@@H]3C[C@H]3OC4=O)C(O[C@H]5CN(C([C@H](C(C)(C)C)N4)=O)[C@H](C(N[C@@]([C@@H]6C=C)(C6)C(NS(C7CC7)(=O)=O)=O)=O)C5)=N2)C=C1
別名

MK-5172
輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Publications (29)

All ELISACell Proliferation/Viability AssayIn Vivo ImagingIn Vivo Efficacy Study

Sort by:

Journal Impact Factor

Signal Transduct Target Ther

Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. [Abstract]

2021 May 29;6(1):212. PMID: 34052830
Nature

Ultra-high-throughput mapping of genetic design space. [Abstract]

2026 Feb;650(8103):1035-1044. PMID: 41535463
Cancer Cell

In vivo models of subclonal oncogenesis and dependency in hematopoietic malignancy. [Abstract]

2024 Nov 11;42(11):1955-1969.e7. PMID: 39532065
Cancer Cell

High-performance multiplex drug-gated CAR circuits. [Abstract]

2022 Nov 14;40(11):1294-1305.e4. PMID: 36084652

Grazoprevir purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2022 Nov 14;40(11):1294-1305.e4. [Abstract]

Primary T cell lines were treated with or without Grazoprevir (all in the presence of target cells), and cytokine levels quantified.

Grazoprevir purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2022 Nov 14;40(11):1294-1305.e4. [Abstract]

Cytotoxicity response of OFF VIPER CAR T cells to Grazoprevir being added, washed out, and re-introduced after two days.

Grazoprevir purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2022 Nov 14;40(11):1294-1305.e4. [Abstract]

Grazoprevir dose-response profile of various cells, as measured in cytokine levels and cell killing.

Grazoprevir purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2022 Nov 14;40(11):1294-1305.e4. [Abstract]

IVIS imaging of groups treated with (1) no T cells, (2) non-transduced T cell (NT-WT), (3) ON VIPER CAR T cells, (4) ON VIPER CAR T cells with Grazoprevir (5) OFF VIPER CAR T cells, (6) OFF VIPER CAR T cells with Grazoprevir, or (7) Traditional CAR T cells by day 21.

Grazoprevir purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2022 Nov 14;40(11):1294-1305.e4. [Abstract]

Illustration of the dual-tumor model generated by systemically growing Nalm6 cells via i.v. and regional growth of MSTO-211H cells via s.c (left). Timeline for the in vivo experiment (right). Inducers (Grazoprevir or POM) were injected daily through i.p.
Nat Biotechnol

Multi-input chemical control of protein dimerization for programming graded cellular responses. [Abstract]

2019 Oct;37(10):1209-1216. PMID: 31501561
Nat Methods

Chemogenetic control of gene expression and cell signaling with antiviral drugs. [Abstract]

2018 Jul;15(7):519-522. PMID: 29967495
Nat Commun

Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease. [Abstract]

2020 Sep 4;11(1):4417. PMID: 32887884
Cancer Immunol Res

CRASH-IT Switch Enables Reversible and Dose-Dependent Control of TCR and CAR T-cell Function. [Abstract]

2021 Sep;9(9):999-1007. PMID: 34193461
Elife

Acute disruption of the synaptic vesicle membrane protein synaptotagmin 1 using knockoff in mouse hippocampal neurons. [Abstract]

2020 Jun 9:9:e56469. PMID: 32515733
J Gastroenterol

Combinations of two drugs among NS3/4A inhibitors, NS5B inhibitors and non-selective antiviral agents are effective for hepatitis C virus with NS5A-P32 deletion in humanized-liver mice. [Abstract]

2019 May;54(5):449-458. PMID: 30684016
Pharmaceuticals (Basel)

Evaluation of the Potency of Anti-HIV and Anti-HCV Drugs to Inhibit P-Glycoprotein Mediated Efflux of Digoxin in Caco-2 Cell Line and Human Precision-Cut Intestinal Slices. [Abstract]

2022 Feb 18;15(2):242. PMID: 35215354
Antiviral Res

Identification of a novel replication-competent hepatitis C virus variant that confers the sofosbuvir resistance. [Abstract]

2022 Jan:197:105224. PMID: 34864126
Antiviral Res

Construction and characterization of Genotype-3 hepatitis C virus replicon revealed critical genotype-3-specific polymorphism for drug resistance and viral fitness. [Abstract]

2019 Nov;171:104612. PMID: 31542377
Antiviral Res

A profiling study of a newly developed HCVcc strain PR63cc's sensitivity to direct-acting antivirals. [Abstract]

2017 Mar;139:18-24. PMID: 28025084
Sci Rep

Hepatitis C virus NS3/4A inhibitors and other drug-like compounds as covalent binders of SARS-CoV-2 main protease. [Abstract]

2022 Jul 16;12(1):12197. PMID: 35842458
Sci Rep

Impact of novel NS5A resistance-associated substitutions of hepatitis C virus detected in treatment-experienced patients. [Abstract]

2019 Apr 5;9(1):5722. PMID: 30952914
Development

Small molecule- and cell contact-inducible systems for controlling expression and differentiation in mouse embryonic stem cells. [Abstract]

2025 May 16:dev.204505. PMID: 40377146
J Pharm Biomed Anal

Simultaneous determination of elbasvir and grazoprevir in fixed-dose combination and mass spectral characterization of each degradation product by UHPLC-ESI-QTOF-MS/MS. [Abstract]

2020 Jan 30;178:112964. PMID: 31711865
J Chromatogr B Analyt Technol Biomed Life Sci

Quantification of second generation direct-acting antivirals daclatasvir, elbasvir, grazoprevir, ledipasvir, simeprevir, sofosbuvir and velpatasvir in human plasma by UPLC-MS/MS. [Abstract]

2019 Mar 15:1110-1111:15-24. PMID: 30776611
bioRxiv

High-resolution profiling reveals coupled transcriptional and translational regulation of transgenes. [Abstract]

2024 Dec 3:2024.11.26.625483. PMID: 39651241
Patent

US12065501.
University of Glasgow

2024 Mar.
bioRxiv

2024 Mar 12.
Research Square Preprint

2024 Jan 23.
bioRxiv

Turn-On Protein Switches for Controlling Actin Binding in Cells. [Abstract]

2023 Oct 26:2023.10.26.561921. PMID: 37961502
bioRxiv

Controlled protein activities with viral proteases, antiviral peptides, and antiviral drugs. [Abstract]

2023 Feb 27:2023.02.27.530290. PMID: 36909459
Patent

US20220025003A1.
Patent

US20190010245A1.
Patent

US20180346589A1.

溶剤 & 溶解度

体外:

Ethanol : 66.67 mg/mL (86.93 mM; Need ultrasonic)

DMSO : 50 mg/mL (65.20 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.3040 mL

6.5198 mL

13.0395 mL

5 mM

0.2608 mL

1.3040 mL

2.6079 mL

10 mM

0.1304 mL

0.6520 mL

1.3040 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (3.26 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (3.26 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 100% PEG-300

Solubility: 12.5 mg/mL (16.30 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

プロトコル

Animal Administration^[1]

Rats and Dogs^[1]
Studies are performed in both rats and dogs. For studies in which Grazoprevir is dosed intravenously to rats or dogs, the compound is formulated in polyethylene glycol 200 (PEG200) and administered as a bolus at either 2 mg/kg of body weight (Rats) or 0.5 mg/kg (dog). For oral studies, the crystalline potassium salt of the compound is dosed as a solution in PEG400 at 5 mg/kg (Rats) or 1 mg/kg (dog). For all studies, blood samples are collected in EDTA-containing tubes at appropriate times and plasma is separated by centrifugation and stored at −70°C until analysis. Quantitation of Grazoprevir (MK-5172) levels is conducted by high-performance liquid chromatography/mass spectroscopy (LC/MS/MS) following protein precipitation. Liver samples are obtained from rat studies at the termination of the experiment. For dog, liver biopsy samples (20 μL) are collected following sedation. Tissue samples are homogenized in four volumes of deionized water, and drug concentrations are determined by LC/MS/MS after protein precipitation.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (286 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Summa V, et al. MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants. Antimicrob Agents Chemother. 2012 Aug;56(8):4161-7. [Content Brief]

[2]. Harper S, et al. Discovery of MK-5172, a Macrocyclic Hepatitis C Virus NS3/4a Protease Inhibitor. ACS Med Chem Lett. 2012 Mar 2;3(4):332-6. [Content Brief]

[3]. Qi Sun, et al. Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. Signal Transduct Target Ther. 2021 May 29;6(1):212. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO / Ethanol	1 mM	1.3040 mL	6.5198 mL	13.0395 mL	32.5988 mL
	5 mM	0.2608 mL	1.3040 mL	2.6079 mL	6.5198 mL
	10 mM	0.1304 mL	0.6520 mL	1.3040 mL	3.2599 mL
	15 mM	0.0869 mL	0.4347 mL	0.8693 mL	2.1733 mL
	20 mM	0.0652 mL	0.3260 mL	0.6520 mL	1.6299 mL
	25 mM	0.0522 mL	0.2608 mL	0.5216 mL	1.3040 mL
	30 mM	0.0435 mL	0.2173 mL	0.4347 mL	1.0866 mL
	40 mM	0.0326 mL	0.1630 mL	0.3260 mL	0.8150 mL
	50 mM	0.0261 mL	0.1304 mL	0.2608 mL	0.6520 mL
	60 mM	0.0217 mL	0.1087 mL	0.2173 mL	0.5433 mL
Ethanol	80 mM	0.0163 mL	0.0815 mL	0.1630 mL	0.4075 mL

Keywords

Grazoprevir

29 Cited Publications

100 mg お問い合わせ

Subscribe to the

MedChemExpress

Newsletter

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

Grazoprevir

Anti-Infection Compound Library

Metabolism/Protease Compound Library

FDA-Approved Drug Library

Antiviral Compound Library

Drug Repurposing Compound Library

Macrocyclic Compound Library

Anti-COVID-19 Compound Library

NMPA-Approved Drug Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Hepatitis C Virus Compound Library

Pediatric Drug Library

EMA-Approved Drug Library

Human Metabolite Library

Protease Inhibitor Library

Highly Selective Inhibitors Library

Anti-Drug-Resistant Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

MedChemExpress（MCE）の使用を引用している文献 Grazoprevir

生物活性

化学情報

Publications (29)

溶剤 & 溶解度

プロトコル

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

Grazoprevir

Anti-Infection Compound Library

Metabolism/Protease Compound Library

FDA-Approved Drug Library

Antiviral Compound Library

Drug Repurposing Compound Library

Macrocyclic Compound Library

Anti-COVID-19 Compound Library

NMPA-Approved Drug Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Hepatitis C Virus Compound Library

Pediatric Drug Library

EMA-Approved Drug Library

Human Metabolite Library

Protease Inhibitor Library

Highly Selective Inhibitors Library

Anti-Drug-Resistant Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

MedChemExpress（MCE）の使用を引用している文献 Grazoprevir

生物活性

化学情報

Publications (29)

溶剤 & 溶解度

プロトコル

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

Grazoprevir 関連分類

製品番号: HY-15298